KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket Capitalization

AbCellera Biologics (ABCL) Return on Equity: 2021-2023

Historic Return on Equity for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2023 value amounting to -0.13%.

  • AbCellera Biologics' Return on Equity fell 25.00% to -0.13% in Q4 2023 from the same period last year, while for Dec 2023 it was -0.13%, marking a year-over-year decrease of 25.00%. This contributed to the annual value of -0.15% for FY2024, which is 2.00% down from last year.
  • Latest data reveals that AbCellera Biologics reported Return on Equity of -0.13% as of Q4 2023, which was down 15.43% from -0.11% recorded in Q3 2023.
  • AbCellera Biologics' Return on Equity's 5-year high stood at 0.32% during Q1 2021, with a 5-year trough of -0.13% in Q4 2023.
  • Over the past 3 years, AbCellera Biologics' median Return on Equity value was 0.16% (recorded in 2021), while the average stood at 0.11%.
  • Data for AbCellera Biologics' Return on Equity shows a maximum YoY tumbled of 31bps (in 2023) over the last 5 years.
  • AbCellera Biologics' Return on Equity (Quarterly) stood at 0.16% in 2021, then fell by 3bps to 0.13% in 2022, then dropped by 25bps to -0.13% in 2023.
  • Its Return on Equity stands at -0.13% for Q4 2023, versus -0.11% for Q3 2023 and -0.06% for Q2 2023.